Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
For hepatocellular carcinoma (HCC) patients on immunotherapy, how you're counseled before treatment may matter as much as the treatment itself. A new study found that patients who completed six cycles of therapy maintained stable quality of life and low regret, while those who dropped out reported worse fatigue and higher decision regret. Researchers say honest, informative counseling — not just reassurance — could make the difference.
For patients with hepatocellular carcinoma (HCC) starting immunotherapy, the conversation before treatment begins may be just as important as the treatment itself. A prospective study published in Supportive Care in Cancer found that patients who completed six cycles of immunotherapy-targeted combination therapy maintained stable quality of life and low decision regret — while those who discontinued experienced worsening fatigue and significantly higher regret.
The study, conducted at a medical center in Taiwan, followed 33 HCC patients through quantitative assessments each treatment cycle and qualitative interviews. Over one-third of patients (36.4%) discontinued therapy, and this group showed a steeper decline in quality-of-life scores and a meaningful increase in decision regret compared to completers. Hope declined across all patients, but was negatively correlated with regret — meaning more regret tracked with less hope.
Researchers concluded that pretreatment counseling should be honest and informative rather than simply reassuring, and that integrating longitudinal patient-reported outcome (PRO) assessments into routine HCC care could improve patient-centered results.
Key Takeaways:
Why it matters: With liver cancer carrying a poor prognosis and complex treatment regimens, setting realistic expectations upfront could help patients make more informed decisions — and potentially stay with life-extending therapies longer.
